Brensocatib Effectiveness Similar for Bronchiectasis With and Without Eosinophilia
According to an analysis from the ASPEN trial, both the 10 mg and 25 mg doses of brensocatib reduced the rate of bronchiectasis exacerbations,...
Triple-Agent Treatment for COPD May Help Achieve Disease Stability
Triple-agent fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) treatment was more effective at achieving and maintaining disease stability in chronic obstructive pulmonary disease (COPD) than double-agent options FF/VI...
Study Examines Myositis-Specific Autoantibody in Idiopathic Inflammatory Myopathy
New research presented at the American Thoracic Society 2025 International Conference may indicate certain protein and pathway differences that could represent opportunities to intervene...
Real-World Data Sheds Light on Non-Cystic Fibrosis Bronchiectasis Treatment
Data are lacking regarding the management of non-cystic fibrosis bronchiectasis (NCFBE) in clinical practice. A recent study presented at the American Thoracic Society 2025...